Tempus AI (NASDAQ:TEM) Stock Price Down 0.3% – Time to Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price was down 0.3% during trading on Wednesday . The company traded as low as $32.97 and last traded at $33.76. Approximately 2,066,504 shares changed hands during trading, an increase of 26% from the average daily volume of 1,636,523 shares. The stock had previously closed at $33.87.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TEM shares. Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Stifel Nicolaus cut Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Loop Capital lifted their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Tempus AI has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Tempus AI Stock Up 1.5 %

The firm has a fifty day moving average price of $49.04 and a two-hundred day moving average price of $46.62. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insiders Place Their Bets

In other Tempus AI news, CEO Eric P. Lefkofsky sold 187,655 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the transaction, the chief executive officer now owns 9,557,283 shares in the company, valued at approximately $358,780,403.82. This represents a 1.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 845,041 shares of company stock valued at $35,125,473.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently modified their holdings of TEM. Kovitz Investment Group Partners LLC purchased a new position in shares of Tempus AI in the third quarter worth approximately $1,367,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after acquiring an additional 1,145,698 shares during the last quarter. Captrust Financial Advisors bought a new stake in shares of Tempus AI during the 3rd quarter valued at $2,726,000. Sigma Planning Corp purchased a new stake in shares of Tempus AI in the 3rd quarter worth $1,323,000. Finally, Dakota Wealth Management bought a new position in Tempus AI in the 3rd quarter worth $1,185,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.